About maia biotechnology inc - MAIA
MAIA Biotechnology, Inc. is a clinical stage biotechnology company that is engaged in the discovery, development and commercialization of therapies targeting cancer. Its product, THIO, is an investigational dual mechanism of action drug candidate incorporating telomere targeting and immunogenicity. The company was founded on August 3, 2018 and is headquartered in Chicago, IL.
MAIA At a Glance
MAIA Biotechnology, Inc.
444 West Lake Street
Chicago, Illinois 60606
| Phone | 1-312-416-8592 | Revenue | 0.00 | |
| Industry | Biotechnology | Net Income | -22,396,172.00 | |
| Sector | Health Technology | Employees | 13 | |
| Fiscal Year-end | 12 / 2026 | |||
| View SEC Filings |
MAIA Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | N/A |
| Price to Book Ratio | 24.874 |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | -1.668 |
| Enterprise Value to Sales | N/A |
| Total Debt to Enterprise Value | N/A |
MAIA Efficiency
| Revenue/Employee | N/A |
| Income Per Employee | -1,722,782.462 |
| Receivables Turnover | N/A |
| Total Asset Turnover | N/A |
MAIA Liquidity
| Current Ratio | 1.662 |
| Quick Ratio | 1.662 |
| Cash Ratio | 1.483 |
MAIA Profitability
| Gross Margin | N/A |
| Operating Margin | N/A |
| Pretax Margin | N/A |
| Net Margin | N/A |
| Return on Assets | -225.541 |
| Return on Equity | -745.235 |
| Return on Total Capital | -942.654 |
| Return on Invested Capital | -745.235 |
MAIA Capital Structure
| Total Debt to Total Equity | N/A |
| Total Debt to Total Capital | N/A |
| Total Debt to Total Assets | N/A |
| Long-Term Debt to Equity | N/A |
| Long-Term Debt to Total Capital | N/A |